CAJ | 학술논문

目的：观察重组人脑利钠肽（rhBNP）治疗心肾综合征患者的疗效。方法：回顾性分析在我院住院诊断为心肾综合征的患者75例的资料，按数字表法被随机分为：常规治疗组（40例，给予常规治疗），rhBNP组（35例，在常规治疗的基础上加用 rhBNP），rhBNP按0.0075μg·kg-1·min-1以微量泵静脉泵入，每天1次，每次持续约10 h，7d为1疗程，分别记录治疗前和7d后患者的24 h尿量、N末端脑利钠肽前体（NT-proBNP）、肾小球滤过率及心脏彩超的变化。结果：治疗后与常规治疗组比较， rhBNP 组总有效率（62.5％比94.3％），24 h 尿量[（785.2±143.4）ml比（965.34±171.8）ml]、肾小球滤过率[（34.1±2.6）ml/min比（45.2±5.6）ml/min]、左室射血分数[（35.6±5.5）％比（45.9±6.8）％]显著升高，NT-proBNP [（3451.1±1314.2）pg/ml 比（1516.43±431.52）pg/ml]水平显著降低，差异有统计学意义（P均＜0.01）。结论：重组人脑利钠肽在心肾综合征患者治疗中安全有效，并能改善肾功能。
목적：관찰중조인뇌리납태（rhBNP）치료심신종합정환자적료효。방법：회고성분석재아원주원진단위심신종합정적환자75례적자료，안수자표법피수궤분위：상규치료조（40례，급여상규치료），rhBNP조（35례，재상규치료적기출상가용 rhBNP），rhBNP안0.0075μg·kg-1·min-1이미량빙정맥빙입，매천1차，매차지속약10 h，7d위1료정，분별기록치료전화7d후환자적24 h뇨량、N말단뇌리납태전체（NT-proBNP）、신소구려과솔급심장채초적변화。결과：치료후여상규치료조비교， rhBNP 조총유효솔（62.5％비94.3％），24 h 뇨량[（785.2±143.4）ml비（965.34±171.8）ml]、신소구려과솔[（34.1±2.6）ml/min비（45.2±5.6）ml/min]、좌실사혈분수[（35.6±5.5）％비（45.9±6.8）％]현저승고，NT-proBNP [（3451.1±1314.2）pg/ml 비（1516.43±431.52）pg/ml]수평현저강저，차이유통계학의의（P균＜0.01）。결론：중조인뇌리납태재심신종합정환자치료중안전유효，병능개선신공능。
Objective:To observe the therapeutic effect of recombinant human brain natriuretic peptide (rhBNP)on patients with cardiorenal syndrome.Methods:The data of 75 patients,who were diagnosed as cardiorenal syndrome and hospitalized in our hospital,were retrospectively analyzed.They were randomly divided into routine treatment group (n=40,received routine treatment)and rhBNP group (n=35,received rhBNP based on routine treatment) according to number table method.The rhBNP was pumped with 0.0075μg·kg-1 ·min-1 using micropump intrave-nously,once/day,about 10h/time and 7d was regarded as a course of treatment.Changes of 24h urine volume,N terminal pro brain natriuretic peptide (NT-proBNP),glomerular filtration rate (GFR)and echocardiograph were recorded in all patients before and 7d after treatment.Results:Compared with routine treatment group after treat-ment,there were significant increase in total effective rate (62.5% vs.94.3%),24h urine volume [(785.2 ± 143.4)ml vs.(965.34±171.8)ml],GFR [(34.1±2.6)ml/min vs.(45.2±5.6)ml/min]and left ventricular e-jection fraction [(35.6±5.5)% vs.(45.9±6.8)%],and significant reduction in NT-proBNP level [(3451.1± 1314.2)pg/ml vs.(1516.43 ± 431.52)pg/ml]in rhBNP group,P<0.01 all.Conclusion:Recombinant human brain natriuretic peptide is safe,effective and can improve renal function in treating patients with cardiorenal syn-drome.